Antiplatelet drug use in a diabetic clinic

QJM: An International Journal of Medicine

Volumn 100, Issue 9, 2007, Pages 547-550

  Woodward, Ann ^a   Bayley, D ^a   Overend, L ^a   Gill, G ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HEMOGLOBIN A1C;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG USE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TEACHING HOSPITAL;

EID: 34548218333     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm058     Document Type: Article

References (14)

1. Joint British Societies. JBS 2: Joint British Societies Guidelines on Prevention of Cardiovascular Disease in Clinical Practice. Heart 2005; 91(Suppl. 5):v1-52.
2. American Diabetes Association.Standards of Medical Care in Diabetes - 2006. Diabetes Care 2006; 29:S4-42.
3. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. for the Hot Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351:1755-62.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:29-34.
5. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who have had a myocardial infarction: Cross sectional and cohort studies. Br Med J 2002; 324:939-42.
6. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients. Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26:3264-3272.
7. CAPRIE Steering Committee.A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-39.
8. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90:625-8.
9. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl. 2):S1-29.
10. American Diabetes Association Position Statement. Aspirin therapy in Diabetes. Diabetes Care 1997; 20:1772-3.
11. Williams B, Poulter NR, Brown MJ, Davis M, McInnes G, Potter JF, et al. for the BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-1V): Summary. Br Med J 2004; 328:634-40.
12. Cull CA, Neil HAW, Holman RR. Changing aspirin use in patients with type 2 diabetes in the UKPDS. Diabet Med 2004; 21:1368-71.
13. Barwell N, Marshall G, McDougall C, Brady AJB, Fisher M. Should all diabetic patients receive aspirin? Results from recent trials. Br J Cardiol 2005; 12:275-83.
14. Miller SR, Littenberg B, MacLean CD. Prevalence of antiplatelet therapy in patients with diabetes. Cardiovasc Diabetol 2005; 4:18.